arteriosclerosis atherosclerosis
Conditions
Interventions
Amyloid
Atherosclerosis
Flutemetamol
PET/MRI
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Age 18 years and older (no maximum age) Informed consent by signed informed consent form regarding this study Either: Patients, who are scheduled for carotid endarterectomy (CEA) Or: Patients who are not scheduled to undergo a CEA, but have experienced a TIA/CVA/amaurosis fugax within the last 14 days and at least a 30% stenosis of the symptomatic carotid artery as based on imaging.
Exclusion criteria
Exclusion criteria: Severe cognitive impairment, neurological deficit or comorbidity causing the study to be too high a burden for the patient or disrupting patient*s co-operation with scan procedures. Evident other causality for stroke (cardiac embolus, small vessel disease, carotid dissection or thrombogenic diathesis). Pregnant women and nursing mothers. Contra-indications for MRI. *Relative contra-indications for MRI-contrast agent: GFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tracer uptake in the carotid artery will be correlated to vulnerable plaque characteristics on MRI. In the 5-10 CEA patients, tracer uptake and MR imaging of different plaque characteristics will be validated with plaque histology of the surgically removed specimen. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tracer uptake in the brain. Tracer uptake in the coronary arteries. Radiological characteristics of (early) dementia, as assessed with brain MRI. Medication use. Cognitive symptoms based on subjective complaints prior to hospitalization. | — |
Countries
The Netherlands
Outcome results
None listed